Hypertension is the most common cause of ICH, and the 2015 AHA/ASA ICH guidelines contain a new prevention- focused recommendation for the initiation of blood pressure control immediately after ICH onset.1,2 The related new perfor- mance measure does not apply to specific targets or agents for acute blood pressure control in patients with ICH in the emer- gency department or intensive care unit. Rather, it focuses on the initiation of blood pressure treatment during the inpatient setting with the goal of improving long-term blood pressure management for purposes of secondary prevention. The writ- ing group ideally preferred a measure that directly assessed achieving long-term blood pressure control as an outpatient after ICH. However, development of this into a performance measure was not considered feasible or actionable at this time because of the often limited information on outpatient records and the challenge of following up with patients who may be seen in different healthcare systems. Thus, this new perfor- mance measure requires that patients with ICH are prescribed a pharmacological antihypertensive treatment at the time of hospital discharge or have a documented blood pressure indi- cating that they do not have hypertension. As a new perfor- mance measure, pilot testing is warranted, and it is hoped that, with the advance of electronic medical records, a future per- formance measure might target documentation of long-term compliance and control. The new AHA definition of hyperten- sion as a blood pressure >130/80 mmHg was incorporated as the target for initiation of treatment.34 Corticosteroids are not recommended for treating elevated intracranial pressure or cerebral edema in patients with ICH.2 There is limited information on the extent to which this still occurs. 